In the high-stakes world of pharmaceutical intellectual property, where a single patent can shield billions in revenue and a decade […]

The global pharmaceutical industry stands at a pivotal juncture. While established markets continue to offer stability, the undeniable trajectory of

Part 1: The Bedrock of Biosimilarity: Foundational Principles Beyond “Generic Biologics”: A New Paradigm for Competition and Access In the

In the intricate and often contentious world of American healthcare, a powerful and unsustainable collision is underway. On one side,

Executive Summary The advent of biosimilars represents the most significant structural shift in the biopharmaceutical landscape since the Hatch-Waxman Act

Have you ever looked at your “3-month supply” of medication and done the math? A typical quarter of the year—say,

The global generic drug market presents a fundamental paradox for the executives who navigate its complexities. On one hand, it

China has established itself as the undisputed powerhouse in the global Active Pharmaceutical Ingredients (API) market, particularly dominating the generic

Introduction: The Generic Paradox – Navigating a World of Brutal Competition and Essential Value The generic pharmaceutical industry operates at